A strong procedure franchise and disciplined innovation can compound per-share earnings over time. Q2 sales grew 9.4% to $6.589 billion, supporting the durability of demand. The valuation question is whether the entry price provides enough return after accounting for a premium-quality business that is already widely recognized. Product quality and capital allocation remain more important than short-term multiple expansion.

What the Market May Be Mispricing

Debate	Research judgment
Procedure growth and Mako utilization	A strong procedure franchise and disciplined innovation can compound per-share earnings over time.
Innovation, clinical quality and pricing	Surgeon adoption, procedure volumes, installed-system utilization and recurring implant contribution determine customer economics.
Acquisition returns, leverage and cash conversion	TTM FCF was about $4.70 billion and SBC $251 million, giving a stronger owner-cash profile than many growth peers.

Stryker sells orthopedic implants, surgical equipment, neurotechnology and other medical devices. Mako robotic systems support procedure adoption and implant demand, while consumables and service relationships create recurring revenue. Hospitals and surgeons value clinical outcomes, workflow, training and reliability. Acquisitions broaden the product portfolio but add integration and financing requirements.

Business Takeaway

Stryker sells orthopedic implants, surgical equipment, neurotechnology and other medical devices. Surgeon adoption, procedure volumes, installed-system utilization and recurring implant contribution determine customer economics.

Aging populations, surgical access and robotic adoption support demand. Reimbursement, hospital budgets and competing implant and device platforms constrain growth. Capital systems and recurring implants have different economics and should not be combined into one undifferentiated TAM.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
Zimmer Biomet (ZBH)	Direct: orthopedic implants and robotic-assisted surgery	Product scope; no matched operating-scale series	Competes for orthopedic procedures	Customer choice in the stated segment only
Johnson & Johnson — DePuy Synthes	Direct: orthopedic implants and VELYS enabling technology	Product scope; no matched operating-scale series	Competes for joint-replacement adoption	Customer choice in the stated segment only
Smith+Nephew	Direct: orthopedics, sports medicine and surgical workflows	Product scope; no matched operating-scale series	Competes in selected musculoskeletal procedures	Customer choice in the stated segment only
Medtronic (MDT)	Segment-specific: neurovascular and selected surgical technology	Product scope; no matched operating-scale series	Limited procedure-level overlap	Customer choice in the stated segment only

Industry Takeaway

Capital systems and recurring implants have different economics and should not be combined into one undifferentiated TAM. The base case requires evidence of profitable adoption within that market.

Competitive Landscape

Orthopedic implants and surgical robotics require orthopedic peers. Boston Scientific is removed as a broad device anchor; Medtronic is relevant only in identified neurovascular/surgical segments.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Zimmer Biomet (ZBH)	No consistent comparable series	Direct: orthopedic implants and robotic-assisted surgery	Implant installed base and ROSA ecosystem	Different surgical-equipment and neurotechnology mix	Competes for orthopedic procedures
Johnson & Johnson — DePuy Synthes	No consistent comparable series	Direct: orthopedic implants and VELYS enabling technology	Surgeon relationships and orthopedic portfolio	Parent pharmaceuticals do not represent device economics	Competes for joint-replacement adoption
Smith+Nephew	No consistent comparable series	Direct: orthopedics, sports medicine and surgical workflows	Specialized procedure products	Different business mix and robotics footprint	Competes in selected musculoskeletal procedures
Medtronic (MDT)	No consistent comparable series	Segment-specific: neurovascular and selected surgical technology	Hospital and neurological-device distribution	Not a joint-replacement implant competitor	Limited procedure-level overlap

Moat Assessment

Clinical reputation, surgeon relationships, installed robotics and distribution create a strong moat. Competitors remain well funded and can improve products. Sustaining the moat requires continuing clinical and engineering investment.

Moat direction: Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Clinical reputation, surgeon relationships, installed robotics and distribution create a strong moat. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2024	22,595	10.23%	64.37%	21.93%	3,487	15.43%	229	386	4,493	14,120
FY2025	25,116	11.16%	65.04%	22.92%	4,283	17.05%	243	387	4,100	16,360
Q1 FY2026	$6,020	N/D	63.3%	15.5%	$415 (derived: CFO - capex)	6.9%	$87	386.5	$2,878	N/D
Q2 FY2026	$6,589	N/D	68.3%	25.2%	$1,059 (derived: current YTD - prior YTD)	16.1%	$54 (derived: current YTD - prior YTD)	386	$3,391	N/D
H1 FY2026	$12,609	N/D	65.9%	20.6%	$1,474 (derived: CFO - capex)	11.7%	$141	386.2	$3,391	N/D
Q3 FY2026	$6,520	N/D	65.2%	15.9%	$1,224 (derived: current YTD - prior YTD)	18.8%	$67 (derived: current YTD - prior YTD)	384.7	$3,271	N/D
9M FY2026	$19,129	N/D	65.6%	19.0%	$2,698 (derived: CFO - capex)	14.1%	$208	385.8	$3,271	N/D

Financial Takeaways

TTM FCF was about $4.70 billion and SBC $251 million, giving a stronger owner-cash profile than many growth peers. Debt remains material after acquisitions. Scenario EPS includes ongoing costs, while an assumed dividend stream is valued separately. The model does not rely on a return to historically high valuation multiples. The latest call described peripheral-vascular disruption and orthopedic backorders. The narrowed revenue outlook requires second-half recovery, including rescheduled procedures. Strong cash generation does not remove this operational dependency.

Financial direction: Mixed — assess the reported trend alongside dilution and the balance sheet.

Current Valuation

Metric	Value
Price Snapshot	$310.55 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	$116.76B
Enterprise Value	$128.73B
Trailing P/E	31.55
Provider forward P/E	19.12
EV / Sales	4.98

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	EV / Sales	Growth / Margin / Risk Context
SYK — Stryker Corporation	Subject company	Public	19.12	4.98	orthopedics and medical technology; 3Y revenue-growth estimate 8.22%; operating margin 23.82%
ZBH — Zimmer Biomet	Direct orthopedic/robotics comparator	Public	10.97	2.99	orthopedic implants and surgical technology; 3Y revenue-growth estimate 3.94%; operating margin 16.65%
MDT — Medtronic plc	Segment-specific neurovascular/surgical overlap; not an orthopedic peer	Public	15.76	3.60	diversified medical devices; 3Y revenue-growth estimate 5.20%; operating margin 20.10%
Johnson & Johnson — DePuy Synthes	Direct: orthopedic implants and VELYS enabling technology	Operating product / listed parent	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes for joint-replacement adoption
Smith+Nephew	Direct: orthopedics, sports medicine and surgical workflows	Public	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes in selected musculoskeletal procedures

Comparable takeaway: Orthopedic implants and surgical robotics require orthopedic peers. Boston Scientific is removed as a broad device anchor; Medtronic is relevant only in identified neurovascular/surgical segments. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 24×, versus the provider's current forward P/E of 19.12×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of $231.51, versus the central base FV of $288.60. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	3Y revenue CAGR 4%; sustainable 2029 EPS $10.50 after compensation; 18× P/E; 11% discount rate; Slower procedures and pricing pressure leave 2029 sustainable EPS at $10.50.	$146.02	25%	Execution, financing or competitive setbacks remain credible	-53.0%
Base	3Y revenue CAGR 8%; sustainable 2029 EPS $16.00 after compensation; 24× P/E; 11% discount rate; Steady innovation and operating leverage produce $16 of 2029 sustainable EPS.	$288.60	50%	Most likely operating trajectory, requiring measurable progress	-7.1%
Bull	3Y revenue CAGR 12%; sustainable 2029 EPS $21.00 after compensation; 29× P/E; 11% discount rate; Strong procedure and platform adoption produce $21 of 2029 sustainable EPS.	$453.12	25%	Successful product conversion and operating leverage; not assured	+45.9%
Probability-Weighted	Sum of each scenario value × its probability	$294.09	100%	Judgmental scenario probabilities	-5.3%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
• Cross-check methods: Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in the valuation workpaper.
• Key valuation dependencies: Procedure growth and Mako utilization; Innovation, clinical quality and pricing; Acquisition returns, leverage and cash conversion. All forward figures are independent research assumptions, not company guidance or consensus.
• Valuation confidence / Risk Level: 72/100 / Medium. Scenario values are sensitive to sustainable earnings and terminal multiples.
• Margin-of-safety conclusion: Hold / Watch at $304.40. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

Management has a strong record of execution and portfolio development. Acquisition discipline, integration returns and deleveraging remain relevant. Monitor organic growth and per-share cash returns rather than rewarding acquired revenue without considering price paid. Supply disruptions weaken the immediate execution assessment. M&A remains management's first capital-allocation priority, so acquisition returns should be tested alongside recovery of organic growth.

Management Takeaway

M&A remains management's first capital-allocation priority, so acquisition returns should be tested alongside recovery of organic growth.

Analyzed call: Q2 2026, complete material Q&A · Research snapshot: 2026-10-21

The table consolidates related questions and follow-ups from each material participant in the complete call.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Joanne Wuensch / Citi	Why was the guidance range narrowed?	Management said recovery is progressing and the range reflects remaining uncertainty.	Treat the stated timetable as conditional on demonstrated execution.
Robbie Marcus / JPMorgan	What changed in underlying demand?	Management said peripheral vascular disruption was unexpected.	Confirm that this opportunity converts into profitable recurring demand.
Larry Biegelsen / Wells Fargo	What supports the second-half growth bridge and higher guidance floor?	Management said the higher floor reflects greater confidence.	Confirm that this opportunity converts into profitable recurring demand.
Ryan Zimmerman / BTIG	How do margins and outpatient care settings support EPS?	Management said margin execution and outpatient opportunities support earnings.	Require durable cash conversion after compensation and ongoing investment.
Travis Steed / Bank of America	How quickly can orthopedic supply recover?	Management said backorders delay a full recovery.	Confirm that this opportunity converts into profitable recurring demand.
Vik Chopra / BMO Capital Markets	Can management quantify the volume assumptions behind recovery?	Management did not quantify all recovery drivers.	Confirm that this opportunity converts into profitable recurring demand.
Matthew O'Brien / Piper Sandler	How does guidance reflect known operating problems?	Management said identified operational problems are incorporated into guidance.	Treat the stated timetable as conditional on demonstrated execution.
Vijay Kumar / Evercore ISI	How are acquisitions prioritized relative to buybacks?	Management said acquisitions remain the leading priority.	Judge allocation on per-share returns after financing and dilution.
Patrick Wood / UBS	What supports the Smart Care sales outlook?	Management said strong orders support later-year sales.	Confirm that this opportunity converts into profitable recurring demand.
Ravi Misra / Truist	When could vascular products and trial evidence contribute?	Management said approval and evidence timing remain uncertain.	Value the opportunity only as permissions and evidence mature.
Matt Taylor / Jefferies	How will disruption-related procedure delays affect recovery?	Management said rescheduled procedures contribute later.	Treat the stated timetable as conditional on demonstrated execution.
Mathew Blackman / TD Cowen	What is needed to accelerate Inari growth?	Management said supply fixes are needed for faster growth.	Confirm that this opportunity converts into profitable recurring demand.
Caitlin Roberts / Canaccord Genuity	How do innovation and manufacturing affect the full-year outlook?	Management maintained the narrowed full-year outlook.	Confirm that this opportunity converts into profitable recurring demand.

Analyst-Q&A Takeaway

The recovery bridge depends on resolving supply constraints and converting delayed procedures. Strong orders help, but management did not quantify every recovery driver; acquisition discipline remains relevant.

Source	Type	Date / Period	What It Supports
www.sec.gov	Company IR / earnings filing	Q2 2026	Latest operating results, guidance, products and financial supplement
SYK complete earnings-call transcript	Transcript	Q2 2026	Prepared remarks and all material Q&A exchanges
SYK regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
SYK valuation statistics	Market data	2026-10-20 close; ratios retrieved 2026-10-21	Market capitalization, shares, quoted multiples and current ratios
SYK historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
SYK historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
SYK historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Zimmer Biomet statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
Medtronic plc statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
2025 10-K — product categories and competitive markets	Regulatory filing / primary product evidence	FY2025; checked 2026-10-28	Orthopedic versus neuro/surgical device boundaries
SEC XBRL company facts — SYK	Regulatory filing (as tagged)	FY2026, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics

Research context

• Company: Stryker Corporation

• Ticker: SYK

• Exchange: NYSE

• Sector / Industry: Health Care / orthopedics and medical technology

• Template version: 2.7

• Research date: 2026-10-21

• Valuation / score price snapshot: $310.55 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: Primary Watchlist

• Owned: Yes

• Primary operating period reviewed: Q2 2026

• Historical period reviewed: TTM, FY 2025, FY 2024; latest balance-sheet date shown below

• Latest investor presentation reviewed: Results release and associated financial tables; no separate slide deck materially used

• Latest earnings call reviewed: Q2 2026, complete material Q&A

• Latest post-earnings management commentary reviewed: No separate later management presentation incorporated

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

SYK — Stryker Corporation

Company & Research Metadata

• Company: Stryker Corporation

• Ticker: SYK

• Exchange: NYSE

• Sector / Industry: Health Care / orthopedics and medical technology

• Template version: 2.7

• Research date: 2026-10-21

• Valuation / score price snapshot: $310.55 — 2026-11-03 regular-session close, America/New_York

• Tracking tier: Primary Watchlist

• Owned: Yes

• Primary operating period reviewed: Q2 2026

• Historical period reviewed: TTM, FY 2025, FY 2024; latest balance-sheet date shown below

• Latest investor presentation reviewed: Results release and associated financial tables; no separate slide deck materially used

• Latest earnings call reviewed: Q2 2026, complete material Q&A

• Latest post-earnings management commentary reviewed: No separate later management presentation incorporated

• Price snapshot date: 2026-11-03

• Price snapshot time / timezone: Regular-session close, America/New_York (including exchange half-days)

• Competitor / analyst-Q&A audit: 2026-10-28; original operating, price and valuation snapshots retained.

What's Changed Since Previous Review

Current Review: 2026-10-28

Previous Review: 2026-10-21

Update Trigger: Competitor relevance and analyst-Q&A correction

Area	Previous View	Current View	Investment Impact
Competition	Preceding operating and comparable-company classifications	Product/customer/geographic boundaries corrected; direct rivals separated from substitutes, partners and valuation anchors	Corrects the competitive comparison; does not by itself re-underwrite the valuation
Analyst questions	Prior source-linked Q&A summaries	Complete questions and sentence-form management answers; all 13 existing rows retained	Improves readability while preserving the recorded exchange meaning
Valuation and scores	Approved operating/price snapshots, scenarios, scores and decisions	Preserved	No price refresh, rerank or change to valuation assumptions in this correction pass

Thesis: No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

Investment Snapshot

Metric	Current View
Price Snapshot	$310.55 — 2026-11-03 regular-session close, America/New_York
Rating / Zone Status	Hold / Watch
Bear / Base / Bull Fair Value	$146.02 / $288.60 / $453.12
Scenario Probabilities	25% / 50% / 25%
Probability-Weighted Fair Value	$294.09
Probability-Weighted Expected Return	-5.3%
Bear-Case Return	-53.0%
Strong Buy Zone	≤ $160.62
Buy Zone	>$160.62–$235.27
Avoid Chasing Above	> $326.77
Quality Score / Tier	85.0 / Tier A
Opportunity Score / Rank	50.1 / #44 of 76
Risk Level	Medium
Tracking / Ownership	Primary Watchlist / Owned

Decision rationale: SYK is Hold / Watch at $304.40, with -3.4% probability-weighted upside and -52.0% bear-case return. A strong procedure franchise and disciplined innovation can compound per-share earnings over time. Confidence is 72/100 because the earnings conversion, competitive and capital assumptions below remain conditional.

Investment Thesis

A strong procedure franchise and disciplined innovation can compound per-share earnings over time. Q2 sales grew 9.4% to $6.589 billion, supporting the durability of demand. The valuation question is whether the entry price provides enough return after accounting for a premium-quality business that is already widely recognized. Product quality and capital allocation remain more important than short-term multiple expansion.

What the Market May Be Mispricing

Debate	Research judgment
Procedure growth and Mako utilization	A strong procedure franchise and disciplined innovation can compound per-share earnings over time.
Innovation, clinical quality and pricing	Surgeon adoption, procedure volumes, installed-system utilization and recurring implant contribution determine customer economics.
Acquisition returns, leverage and cash conversion	TTM FCF was about $4.70 billion and SBC $251 million, giving a stronger owner-cash profile than many growth peers.

Business Overview

Stryker sells orthopedic implants, surgical equipment, neurotechnology and other medical devices. Mako robotic systems support procedure adoption and implant demand, while consumables and service relationships create recurring revenue. Hospitals and surgeons value clinical outcomes, workflow, training and reliability. Acquisitions broaden the product portfolio but add integration and financing requirements.

Business Takeaway

Stryker sells orthopedic implants, surgical equipment, neurotechnology and other medical devices. Surgeon adoption, procedure volumes, installed-system utilization and recurring implant contribution determine customer economics.

Industry, TAM & Market Share

Aging populations, surgical access and robotic adoption support demand. Reimbursement, hospital budgets and competing implant and device platforms constrain growth. Capital systems and recurring implants have different economics and should not be combined into one undifferentiated TAM.

Market-Share Analysis

Comparable same-definition share data for the subject and its principal rivals were not established. TAM estimates and company-specific volume measures are not treated as directly comparable market shares. The positioning analysis below is more reliable than a table of unmatched percentages.

Competitive Scale / Position

Company / Platform	Primary Position	Relative Scale	Growth Direction	Investment Relevance
Zimmer Biomet (ZBH)	Direct: orthopedic implants and robotic-assisted surgery	Product scope; no matched operating-scale series	Competes for orthopedic procedures	Customer choice in the stated segment only
Johnson & Johnson — DePuy Synthes	Direct: orthopedic implants and VELYS enabling technology	Product scope; no matched operating-scale series	Competes for joint-replacement adoption	Customer choice in the stated segment only
Smith+Nephew	Direct: orthopedics, sports medicine and surgical workflows	Product scope; no matched operating-scale series	Competes in selected musculoskeletal procedures	Customer choice in the stated segment only
Medtronic (MDT)	Segment-specific: neurovascular and selected surgical technology	Product scope; no matched operating-scale series	Limited procedure-level overlap	Customer choice in the stated segment only

Industry Takeaway

Capital systems and recurring implants have different economics and should not be combined into one undifferentiated TAM. The base case requires evidence of profitable adoption within that market.

Customer Economics

Surgeon adoption, procedure volumes, installed-system utilization and recurring implant contribution determine customer economics. Training and workflow integration create switching costs. Pricing pressure and manufacturing or quality issues can offset volume growth, making cash margins and product mix important.

Customer-Economics Takeaway

The economic test is Acquisition returns, leverage and cash conversion. Pricing pressure and manufacturing or quality issues can offset volume growth, making cash margins and product mix important.

Competitive Landscape & Moat

Competitive Landscape

Orthopedic implants and surgical robotics require orthopedic peers. Boston Scientific is removed as a broad device anchor; Medtronic is relevant only in identified neurovascular/surgical segments.

Competitor	Market Share	Positioning	Advantages vs. Company	Disadvantages vs. Company	Current Direction
Zimmer Biomet (ZBH)	No consistent comparable series	Direct: orthopedic implants and robotic-assisted surgery	Implant installed base and ROSA ecosystem	Different surgical-equipment and neurotechnology mix	Competes for orthopedic procedures
Johnson & Johnson — DePuy Synthes	No consistent comparable series	Direct: orthopedic implants and VELYS enabling technology	Surgeon relationships and orthopedic portfolio	Parent pharmaceuticals do not represent device economics	Competes for joint-replacement adoption
Smith+Nephew	No consistent comparable series	Direct: orthopedics, sports medicine and surgical workflows	Specialized procedure products	Different business mix and robotics footprint	Competes in selected musculoskeletal procedures
Medtronic (MDT)	No consistent comparable series	Segment-specific: neurovascular and selected surgical technology	Hospital and neurological-device distribution	Not a joint-replacement implant competitor	Limited procedure-level overlap

Moat Assessment

Clinical reputation, surgeon relationships, installed robotics and distribution create a strong moat. Competitors remain well funded and can improve products. Sustaining the moat requires continuing clinical and engineering investment.

Moat direction: Stable — an analytical judgment about product and distribution economics, not a measured market-share claim.

Competitive Takeaway

Clinical reputation, surgeon relationships, installed robotics and distribution create a strong moat. The direct rivals determine commercial pressure; diversified or sector anchors provide valuation context and are not substitutes for direct competition.

Financial Profile

Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

Period	Revenue	Growth	Gross Margin	Operating Margin	FCF	FCF Margin	SBC	Diluted Shares	Cash	Debt
FY2024	22,595	10.23%	64.37%	21.93%	3,487	15.43%	229	386	4,493	14,120
FY2025	25,116	11.16%	65.04%	22.92%	4,283	17.05%	243	387	4,100	16,360
Q1 FY2026	$6,020	N/D	63.3%	15.5%	$415 (derived: CFO - capex)	6.9%	$87	386.5	$2,878	N/D
Q2 FY2026	$6,589	N/D	68.3%	25.2%	$1,059 (derived: current YTD - prior YTD)	16.1%	$54 (derived: current YTD - prior YTD)	386	$3,391	N/D
H1 FY2026	$12,609	N/D	65.9%	20.6%	$1,474 (derived: CFO - capex)	11.7%	$141	386.2	$3,391	N/D
Q3 FY2026	$6,520	N/D	65.2%	15.9%	$1,224 (derived: current YTD - prior YTD)	18.8%	$67 (derived: current YTD - prior YTD)	384.7	$3,271	N/D
9M FY2026	$19,129	N/D	65.6%	19.0%	$2,698 (derived: CFO - capex)	14.1%	$208	385.8	$3,271	N/D

Financial Takeaways

TTM FCF was about $4.70 billion and SBC $251 million, giving a stronger owner-cash profile than many growth peers. Debt remains material after acquisitions. Scenario EPS includes ongoing costs, while an assumed dividend stream is valued separately. The model does not rely on a return to historically high valuation multiples. The latest call described peripheral-vascular disruption and orthopedic backorders. The narrowed revenue outlook requires second-half recovery, including rescheduled procedures. Strong cash generation does not remove this operational dependency.

Financial direction: Mixed — assess the reported trend alongside dilution and the balance sheet.

Management & Capital Allocation

Management has a strong record of execution and portfolio development. Acquisition discipline, integration returns and deleveraging remain relevant. Monitor organic growth and per-share cash returns rather than rewarding acquired revenue without considering price paid. Supply disruptions weaken the immediate execution assessment. M&A remains management's first capital-allocation priority, so acquisition returns should be tested alongside recovery of organic growth.

Management Takeaway

M&A remains management's first capital-allocation priority, so acquisition returns should be tested alongside recovery of organic growth.

Valuation

Current Valuation

Metric	Value
Price Snapshot	$310.55 — 2026-11-03 regular-session close, America/New_York
Market Capitalization	$116.76B
Enterprise Value	$128.73B
Trailing P/E	31.55
Provider forward P/E	19.12
EV / Sales	4.98

Comparable Company Analysis

Company	Relevance	Public / Private	Forward P/E	EV / Sales	Growth / Margin / Risk Context
SYK — Stryker Corporation	Subject company	Public	19.12	4.98	orthopedics and medical technology; 3Y revenue-growth estimate 8.22%; operating margin 23.82%
ZBH — Zimmer Biomet	Direct orthopedic/robotics comparator	Public	10.97	2.99	orthopedic implants and surgical technology; 3Y revenue-growth estimate 3.94%; operating margin 16.65%
MDT — Medtronic plc	Segment-specific neurovascular/surgical overlap; not an orthopedic peer	Public	15.76	3.60	diversified medical devices; 3Y revenue-growth estimate 5.20%; operating margin 20.10%
Johnson & Johnson — DePuy Synthes	Direct: orthopedic implants and VELYS enabling technology	Operating product / listed parent	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes for joint-replacement adoption
Smith+Nephew	Direct: orthopedics, sports medicine and surgical workflows	Public	N/D — no matched snapshot collected	N/D — no matched snapshot collected	Competes in selected musculoskeletal procedures

Comparable takeaway: Orthopedic implants and surgical robotics require orthopedic peers. Boston Scientific is removed as a broad device anchor; Medtronic is relevant only in identified neurovascular/surgical segments. Quoted multiples retain their original dated snapshot; missing matched multiples are not estimated. Consolidated parent multiples do not isolate the competing product. No mechanical peer average is used.

The base terminal P/E is 24×, versus the provider's current forward P/E of 19.12×. Holding that quoted multiple constant on this model's 2029 EPS gives an illustrative present value of $231.51, versus the central base FV of $288.60. Earnings definitions differ, so this is a sensitivity check; it makes the dependence on a rerating or derating explicit.

Valuation Scenarios

Scenario	Key Assumptions	Fair Value	Probability	Probability Rationale	Return From Price Snapshot
Bear	3Y revenue CAGR 4%; sustainable 2029 EPS $10.50 after compensation; 18× P/E; 11% discount rate; Slower procedures and pricing pressure leave 2029 sustainable EPS at $10.50.	$146.02	25%	Execution, financing or competitive setbacks remain credible	-53.0%
Base	3Y revenue CAGR 8%; sustainable 2029 EPS $16.00 after compensation; 24× P/E; 11% discount rate; Steady innovation and operating leverage produce $16 of 2029 sustainable EPS.	$288.60	50%	Most likely operating trajectory, requiring measurable progress	-7.1%
Bull	3Y revenue CAGR 12%; sustainable 2029 EPS $21.00 after compensation; 29× P/E; 11% discount rate; Strong procedure and platform adoption produce $21 of 2029 sustainable EPS.	$453.12	25%	Successful product conversion and operating leverage; not assured	+45.9%
Probability-Weighted	Sum of each scenario value × its probability	$294.09	100%	Judgmental scenario probabilities	-5.3%

Valuation Takeaway

• Primary valuation method: Present value of sustainable 2029 equity earnings × scenario P/E, plus assumed interim dividends. The three-year discount horizon approximates late-2029 earning power.
• Cross-check methods: Direct competition, quoted peer multiples, current cash conversion, and the separate revenue/share/net-margin bridge in the valuation workpaper.
• Key valuation dependencies: Procedure growth and Mako utilization; Innovation, clinical quality and pricing; Acquisition returns, leverage and cash conversion. All forward figures are independent research assumptions, not company guidance or consensus.
• Valuation confidence / Risk Level: 72/100 / Medium. Scenario values are sensitive to sustainable earnings and terminal multiples.
• Margin-of-safety conclusion: Hold / Watch at $304.40. New-file boundaries use Strong Buy = min(P/W FV ÷ 1.5, 1.1 × bear FV), Buy upper = P/W FV ÷ 1.25, Avoid above = P/W FV ÷ 0.90. Returns are to present fair value, not annualized returns or price targets for a particular date.

Analyst Questions

The table consolidates related questions and follow-ups from each material participant in the complete call.

Analyst / Firm	Core Question	Management Response	Research Read-Through
Joanne Wuensch / Citi	Why was the guidance range narrowed?	Management said recovery is progressing and the range reflects remaining uncertainty.	Treat the stated timetable as conditional on demonstrated execution.
Robbie Marcus / JPMorgan	What changed in underlying demand?	Management said peripheral vascular disruption was unexpected.	Confirm that this opportunity converts into profitable recurring demand.
Larry Biegelsen / Wells Fargo	What supports the second-half growth bridge and higher guidance floor?	Management said the higher floor reflects greater confidence.	Confirm that this opportunity converts into profitable recurring demand.
Ryan Zimmerman / BTIG	How do margins and outpatient care settings support EPS?	Management said margin execution and outpatient opportunities support earnings.	Require durable cash conversion after compensation and ongoing investment.
Travis Steed / Bank of America	How quickly can orthopedic supply recover?	Management said backorders delay a full recovery.	Confirm that this opportunity converts into profitable recurring demand.
Vik Chopra / BMO Capital Markets	Can management quantify the volume assumptions behind recovery?	Management did not quantify all recovery drivers.	Confirm that this opportunity converts into profitable recurring demand.
Matthew O'Brien / Piper Sandler	How does guidance reflect known operating problems?	Management said identified operational problems are incorporated into guidance.	Treat the stated timetable as conditional on demonstrated execution.
Vijay Kumar / Evercore ISI	How are acquisitions prioritized relative to buybacks?	Management said acquisitions remain the leading priority.	Judge allocation on per-share returns after financing and dilution.
Patrick Wood / UBS	What supports the Smart Care sales outlook?	Management said strong orders support later-year sales.	Confirm that this opportunity converts into profitable recurring demand.
Ravi Misra / Truist	When could vascular products and trial evidence contribute?	Management said approval and evidence timing remain uncertain.	Value the opportunity only as permissions and evidence mature.
Matt Taylor / Jefferies	How will disruption-related procedure delays affect recovery?	Management said rescheduled procedures contribute later.	Treat the stated timetable as conditional on demonstrated execution.
Mathew Blackman / TD Cowen	What is needed to accelerate Inari growth?	Management said supply fixes are needed for faster growth.	Confirm that this opportunity converts into profitable recurring demand.
Caitlin Roberts / Canaccord Genuity	How do innovation and manufacturing affect the full-year outlook?	Management maintained the narrowed full-year outlook.	Confirm that this opportunity converts into profitable recurring demand.

Analyst-Q&A Takeaway

The recovery bridge depends on resolving supply constraints and converting delayed procedures. Strong orders help, but management did not quantify every recovery driver; acquisition discipline remains relevant.

Thesis Monitoring

Driver	Current State	Positive Trigger / Catalyst	Negative Trigger / Falsifier	What It Changes
Procedure growth and Mako utilization	A strong procedure franchise and disciplined innovation can compound per-share earnings over time.	Revenue trajectory sustains approximately 8% annual growth on a comparable basis	Growth remains below the 4% bear assumption over a full operating cycle	Revenue outlook and scenario probabilities
Innovation, clinical quality and pricing	Surgeon adoption, procedure volumes, installed-system utilization and recurring implant contribution determine customer economics.	After-cost earnings progress toward the base implied net margin of 19.0%	Competition, credit losses or service costs make that margin trajectory unattainable	Margins, moat score and valuation multiple
Acquisition returns, leverage and cash conversion	TTM FCF was about $4.70 billion and SBC $251 million, giving a stronger owner-cash profile than many growth peers.	Financing and compensation remain consistent with 385.9M economic shares in the 2029 base case	Required capital or cumulative dilution materially exceeds the model without matching earnings	Financial score, confidence and downside value

Quality & Opportunity Scorecards

Quality Score

Component	Score	Weight	Weighted Contribution	Evidence
Business durability and economics	91	25%	22.8	Surgeon adoption, procedure volumes, installed-system utilization and recurring implant contribution determine customer economics.
Moat and competitive position	88	25%	22.0	Clinical reputation, surgeon relationships, installed robotics and distribution create a strong moat.
Growth runway and durability	79	20%	15.8	Aging populations, surgical access and robotic adoption support demand.
Financial quality and balance sheet	83	15%	12.5	TTM FCF was about $4.70 billion and SBC $251 million, giving a stronger owner-cash profile than many growth peers.
Management, governance and capital allocation	80	15%	12.0	Management has a strong record of execution and portfolio development.
Quality Score	85.0	100%	85.0	Weighted score, independent of ownership and current price

• Quality Tier: A
• Speculative override: None

Opportunity Score

Component	Raw Input	Normalized Score	Weight	Weighted Contribution
Quality	85	85.0	30%	25.5
Probability-weighted upside	-5.3%	39.4	35%	13.8
Bear-case downside	-53.0%	0.0	20%	0.0
Risk / valuation confidence	72	72.0	15%	10.8
Opportunity Score		50.1	100%	50.1

• Opportunity Rank: #44 of 76
• Zone Status: Hold / Watch

Portfolio Context

• Tracking tier: Primary Watchlist
• Owned: Yes
• Tracking source of truth: my_watchlist.md
• Portfolio source of truth: portfolio/holdings.md
• Scoring independence: Ownership, account, shares, position size and cost basis do not change research, valuation, Quality, Opportunity, rank or zones.

Investment Decision History

Timestamp	Price	Rating	Zone Status	Buy Zone	Strong Buy Zone	Avoid Chasing Above	Base FV	P/W FV	P/W Return	Quality	Opportunity / Rank	Change / Rationale
2026-10-21 (America/New_York)	$304.40	Hold / Watch	Hold / Watch	>$160.62–$235.27	≤ $160.62	> $326.77	$288.60	$294.09	-3.4%	85.0	51.4 / #33	Initial missing-file analysis; common-universe ranking; independent scenario assumptions

---

Material Sources

Source	Type	Date / Period	What It Supports
www.sec.gov	Company IR / earnings filing	Q2 2026	Latest operating results, guidance, products and financial supplement
SYK complete earnings-call transcript	Transcript	Q2 2026	Prepared remarks and all material Q&A exchanges
SYK regular-session historical price	Market data	2026-10-20 close	Common price used in returns, scores and zones
SYK valuation statistics	Market data	2026-10-20 close; ratios retrieved 2026-10-21	Market capitalization, shares, quoted multiples and current ratios
SYK historical income statement	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical income statement; source-native currency and definitions
SYK historical balance sheet	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical balance sheet; source-native currency and definitions
SYK historical cash flows	Standardized financial statements	Latest reported period and two preceding fiscal years	Historical cash flows; source-native currency and definitions
Zimmer Biomet statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
Medtronic plc statistics	Comparable-company market data	2026-10-20 regular close	Peer multiples and financial context; public quote basis
2025 10-K — product categories and competitive markets	Regulatory filing / primary product evidence	FY2025; checked 2026-10-28	Orthopedic versus neuro/surgical device boundaries
SEC XBRL company facts — SYK	Regulatory filing (as tagged)	FY2026, through 2026-09-30	Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics